Updates are available Correction dated 2025-02-04
Click to view Correction: https://doi.org/10.1038/s41591-025-03554-5
-
Authors
Adedinsewo, Demilade A. https://orcid.org/0000-0002-8629-2029
Morales-Lara, Andrea Carolina
Afolabi, Bosede B. https://orcid.org/0000-0002-7511-7567
Kushimo, Oyewole A. https://orcid.org/0000-0002-0760-8014
Mbakwem, Amam C.
Ibiyemi, Kehinde F. https://orcid.org/0000-0002-0125-7276
Ogunmodede, James Ayodele
Raji, Hadijat Olaide https://orcid.org/0000-0003-4859-5405
Ringim, Sadiq H. https://orcid.org/0000-0002-5595-195X
Habib, Abdullahi A.
Hamza, Sabiu M. https://orcid.org/0000-0001-5780-6070
Ogah, Okechukwu S.
Obajimi, Gbolahan
Saanu, Olugbenga Oluseun
Jagun, Olusoji E.
Inofomoh, Francisca O. https://orcid.org/0000-0003-1851-8724
Adeolu, Temitope
Karaye, Kamilu M. https://orcid.org/0000-0001-7992-2398
Gaya, Sule A.
Alfa, Isiaka
Yohanna, Cynthia
Venkatachalam, K. L.
Dugan, Jennifer
Yao, Xiaoxi https://orcid.org/0000-0001-9906-7106
Sledge, Hanna J.
Johnson, Patrick W.
Wieczorek, Mikolaj A.
Attia, Zachi I. https://orcid.org/0000-0002-9706-7900
Phillips, Sabrina D.
Yamani, Mohamad H.
Tobah, Yvonne Butler https://orcid.org/0000-0002-0665-1045
Rose, Carl H.
Sharpe, Emily E. https://orcid.org/0000-0003-4232-0718
Lopez-Jimenez, Francisco
Friedman, Paul A. https://orcid.org/0000-0001-5052-2948
Noseworthy, Peter A. https://orcid.org/0000-0002-4308-0456
Carter, Rickey E.
,
-
Funding
Funding for this research was provided by:
Mayo Clinic | Center for Clinical and Translational Science, Mayo Clinic (UL1 TR002377)
- License Information
-
More Information
Article History
Received: 25 June 2024
Accepted: 9 August 2024
First Online: 2 September 2024
Change Date: 4 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-025-03554-5
Competing interests
: D.A.A. is supported by the Mayo Clinic BIRCWH program funded by the NIH (grant no. K12 AR084222). The content of the article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Z.I.A. is a co-inventor of several AI algorithms (including screening for low LVEF, QT tool, aortic stenosis and atrial fibrillation detection during normal sinus rhythm). These have been licensed to Anumana, AliveCor and Eko. The Mayo Clinic and Z.I.A. may benefit from their commercialization. Z.I.A. is a member of the scientific advisory board for Anumana, an AI company, receives stock options for being an inventor of the ejection fraction algorithm and is a consultant for Anumana, AliveCor and XAI.health. P.A.F. is a co-inventor of several AI algorithms (including screening for low LVEF, QT tool, aortic stenosis and atrial fibrillation detection during normal sinus rhythm). These have been licensed to Anumana, AliveCor and Eko. The Mayo Clinic and P.A.F. may benefit from their commercialization. P.A.F. is a member of the scientific advisory board for Anumana, an AI company. F.L.J. in conjunction with the Mayo Clinic has filed patents related to the application of AI to ECG for diagnosis and risk stratification. F.L.J. is a member of the scientific advisory board for Anumana, an AI company. P.A.N. and the Mayo Clinic have filed patents related to the application of AI to ECG for diagnosis and risk stratification and have licensed several AI-ECG algorithms to Anumana. P.A.N. and the Mayo Clinic are involved in potential equity/royalty relationship with AliveCor. P.A.N. is a study investigator in an ablation trial sponsored by Medtronic. P.A.N. also has served on an expert advisory panel for OptumLabs. Y.B.T. has sponsored research grants from HeraMed, Mitre Corp (MSTORC development grant) and the COVID-19 Interactive Care Plan. Y.B.T. also receives know-how royalties for co-development of HeraBEAT from HeraMed Corp. R.E.C. is a scientific advisor for Anumana, an AI-driven health technology company commercializing ECG-based AI solutions. The other authors declare no competing interests.
